New Drug

The Company currently has three product lines (pipelines), PS-001, PS-002, and PS-003, intended for the treatment of type 2 diabetes, type 1 diabetes, and cancer, respectively.

PS-001 is a first-in-class small-molecule drug for the treatment and reversal of type 2 diabetes. Preclinical trials are completed, and Phase I clinical trials are currently underway.

PS-002 is the same small-molecule drug used to treat type 1 diabetes. Preclinical trials are completed, and we are currently preparing for Phase II clinical trials.

PS-003 is a small-molecule drug for the treatment of cancer. Preclinical trials are currently being executed.

We have initiated development collaboration and licensing discussions for PS-001 with seven international pharmaceutical companies. We have executed Confidential Disclosure Agreements (CDAs) and Material Transfer Agreements (MTAs) with several of them, and negotiations with these companies are ongoing.

The opportunity for these pharmaceutical companies to replicate our experimental data reinforces their confidence in licensing the technology. Upon completion of this validation, we will collaborate on clinical trials, with licensing planned for an appropriate stage thereafter.

Regarding the business model, the Company plans a public offering and listing on the emerging stock market to raise R&D capital required for its operations.